

Claims:

Original Claims 1-24 are currently pending in this application. Claims 1, 5, 9, 13 and 21 are amended without prejudice or disclaimer of the subject matter therein. No new matter has been added by such amendments.

In The Claims:

1. (Currently Amended) A method for treating PAN-drug-induced nephrotoxicity in an individual, comprising: administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
2. (Original) The method of claim 1, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.
3. (Original) The method of claim 1, wherein said composition comprises a controlled release formulation of said composition.
4. (Original) The method of claim 1, wherein said composition comprises a prodrug of said estradiol metabolite.
5. (Currently Amended) A method for treating PAN-drug-induced proteinuria in an individual, comprising: administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
6. (Original) The method of claim 5, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.

7. (Original) The method of claim 5, wherein said composition comprises a controlled release formulation of said composition.

8. (Original) The method of claim 5, wherein said composition comprises a prodrug of said estradiol metabolite.

9. (Currently Amended) A method for treating PAN-drug-induced decreases in glomerular filtration rate in an individual, comprising: administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.

10. (Original) The method of claim 9, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.

11. (Original) The method of claim 9, wherein said composition comprises a controlled release formulation of said composition.

12. (Original) The method of claim 9, wherein said composition comprises a prodrug of said estradiol metabolite.

13. (Currently Amended) A method for treating PAN-drug-induced infiltration of inflammatory cells into renal tissue in an individual, comprising: administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.

14. (Original) The method of claim 13, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.

15. (Original) The method of claim 13, wherein said composition comprises a controlled release formulation of said composition.

16. (Original) The method of claim 13, wherein said composition comprises a prodrug of said estradiol metabolite.

17. (Previously Amended) A method for treating drug-induced excessive proliferation of renal cells in an individual, comprising: administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.

18. (Original) The method of claim 17, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.

19. (Original) The method of claim 17, wherein said composition comprises a controlled release formulation of said composition.

20. (Original) The method of claim 17, wherein said composition comprises a prodrug of said estradiol metabolite.

21. (Currently Amended) A method for treating ~~PAN~~-drug-induced excessive extracellular matrix protein production in renal tissue in an individual, comprising: administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.

22. (Original) The method of claim 21, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.

23. (Original) The method of claim 21, wherein said composition comprises a controlled release formulation of said composition.

24. (Original) The method of claim 21, wherein said composition comprises a prodrug of said estradiol metabolite.